Compare Wahed FTSE USA Shariah ETF (HLAL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Summit Therapeutics Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.22, while Summit Therapeutics Inc trades at $14.51 (market cap $10.48B). The key difference: Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HLAL | SMMT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $29.32 |
52-Week Low | $54.05 | $13.05 |
Market Cap | — | $10.48B |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, reflecting modest near-term pressure. Key financial ratios such as P/E, P/S, and ROE are not available in the current dataset, limiting fundamental visibility. A dividend of $0.02 is scheduled for June 2026, indicating a long-term income component. Trading volume and technical levels require additional market data for full context.
The outlook for HLAL hinges on upcoming financial disclosures to assess valuation and profitability. Investment opportunity lies in potential earnings growth and dividend yield, but risks include lack of current fundamental data and market volatility. Investors should await SEC filings for a clearer picture of the company's financial health.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
